Gsa Capital Partners LLP Alaunos Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.12 - $0.5 $109,467 - $456,113	-912,227 Reduced 61.56%	569,566 $74,000
Q2 2023 Aug 14, 2023	BUY	$0.43 - $0.65 $162,891 - $246,231	378,818 Added 34.35%	1,481,793 $755,000
Q1 2023 May 12, 2023	BUY	$0.46 - $0.81 $66,988 - $117,957	145,627 Added 15.21%	1,102,975 $694,000
Q4 2022 Feb 13, 2023	BUY	$0.5 - $261.0 $174,655 - $91.2 Million	349,311 Added 57.45%	957,348 $621,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $344,424 - $107 Million	-331,177 Reduced 35.26%	608,037 $1.05 Million
Q2 2022 Aug 09, 2022	BUY	$0.41 - $1.24 $289,778 - $876,402	706,776 Added 304.07%	939,214 $1.17 Million
Q1 2022 May 11, 2022	BUY	$0.62 - $1.17 $144,111 - $271,952	232,438 New	232,438 $152,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.